FDA Fast Track Designation For Narmafotnib in Advanced Pancreatic Cancer
Posted: 23 September 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib,…
Major $21m Colonial Foundation philanthropic investment to bring future science into disease diagnosis
Posted: 23 September 2024 An outstanding $21 million philanthropic investment will establish a pioneering research centre to advance precision diagnosis for diseases that affect millions of Australians. The Colonial Foundation Diagnostics Centre will use cutting-edge ‘spatial biology’ technologies…
MDMD Masterclass – Meet our experts
MDMD is a holistic venture strategy advisory. We partner with the ambitious to turn ideas into iconic ventures. We engage at critical points of inflexion to prepare companies to be market ready, investment ready or exit ready.…
$34 million for research into stem cell therapies for osteoarthritis and other conditions
Posted: 18 September 2024 The Australian Government is investing $34.5 million in research funding to trial new treatments and therapies aiming to harness the power of stem cells to improve patient outcomes. Research advances over the past 10…
New digital innovation partnership
Posted: 17 September 2024 La Trobe University has welcomed the Victorian Government’s announcement that an industry-led consortium comprising Artesian Capital Management, La Trobe University, University of Melbourne and RMIT University has been selected to establish the Cremorne Digital…
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
Posted: 17 September 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive efficacy and safety results from the TACTI-003 Phase IIb…
Vale Leon Serry, AM
Posted: 13 September 2024 The contributions of biotechnology industry leader Mr Leon Serry, AM are being recognised by BioMelbourne Network as it acknowledges the passing of a steadfast supporter of our sector and of BioMelbourne Network and its…
SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort
Posted: 13 September 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce an update on…
Total ban on the use of adverse genetic testing results in life insurance
Posted: 12 September 2024 The Albanese Government will end the ability to discriminate based on adverse predictive genetic test results by banning their use in life insurance underwriting. Genetic testing can be a life‑saving step for members of…
New medicines could be PBS-listed in just four weeks under a proposal the health minister calls ‘visionary’
Posted: 12 September 2024 Have you ever had to wait for an important and expensive medicine to be subsidised? A new independent review aims to address what has been a longstanding issue in the health system as part…
First Specialist Paediatric Clinical Site Activated, Recruitment Update & Key Appointment
Posted: 12 September 2024 Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to advise that the first clinical site specialising in paediatric kidney disease was activated today in…
World-first Florey research aims to rapidly and accurately screen drugs to treat MND
Posted: 12 September 2024 Florey MND researchers are poised to begin large-scale drug screening of potential treatments for MND thanks to a $5 million grant from the Australian Medical Research Future Fund (MRFF). Project leader Dr Chris Bye…
